News

Feliza Mirasol is the science editor for 

Articles

By approving EBGLYSS (lebrikizumab-lbkz), FDA has made available a new biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topical treatments.

FDA Approval of Lilly's EBGLYSS Provides New Treatment for Atopic Dermatitis

Lilly has increased its manufacturing investment for biologics in Limerick, Ireland, by $1 billion while launching its new $800 million facility in Kinsale.

Lilly Plans to Grow its Biologics Manufacturing Footprint in Ireland with $1.8 Billion Expansion

Patrick Lavery is an Editor for the MJH Life Sciences brands Pharmaceutical Technology and BioPharm International, and their respective websites, 

. He previously spent nearly a decade as a news anchor, reporter, and producer at New Jersey 101.5 FM.

The company said this new commitment to its facility in Germany goes hand in hand with its recently announced ReciPredict, an initiative intended to streamline the product development cycle.

Oral Solid Development and GMP Pilot-Scale Suite Enhancements Part of New Recipharm Investment

Novo Nordisk will use Korro Bio’s OPERA platform to develop RNA editing candidates for two targets to treat cardiometabolic diseases.


Novo Nordisk and Korro Bio Collaborate on Cardiometabolic Treatments

FDA’s latest approval of Imfinzi (durvalumab) in combination with chemotherapy for treating resectable non-small cell lung cancer before and after surgery is based on Phase III trial results showing that the regimen reduced the risk of recurrence, progression, or death by 32%.

FDA Approves AstraZeneca’s Imfinzi for Lung Cancer Treatment

PiaSky (crovalimab) has previously been approved in countries such as the United States and Japan for monthly, subcutaneous use that may be self-administered with adequate training.

Paroxysmal Nocturnal Hemoglobinuria Treatment from Roche is Approved in EU

With the completion of its acquisition of Morphic, Lilly expands its immunology pipeline to include Morphic's oral integrin therapies to address inflammatory bowel disease.

Lilly Completes $3.2 Billion Acquisition of Morphic, Boosting Its IBD Pipeline

Opaganib was given orphan drug designation for the treatment of neuroblastoma in children, which is rare, but the most common infancy malignancy.

RedHill Granted FDA Orphan Drug Designation for Neuroblastoma Treatment

In a 24-week study of patients with PAH, six-minute walking distance improved by an average of 40.8 meters, and risk of death or clinical worsening was reduced by 82%.

Merck Treatment Combined with Other Therapies for Pulmonary Arterial Hypertension Approved by European Commission

The collaboration builds on Novartis’ acquisition of Chinook Therapeutics just over a year ago.

Biopharma News